deng yue

Creó nuevo artículo

2 D

Luvometinib, a highly selective MEK inhibitor: fills a gap in the treatment of rare tumors with dual indications. | #met #cancer #great

Luvometinib, a highly selective MEK inhibitor: fills a gap in the treatment of rare tumors with dual indications.

Luvometinib, a highly selective MEK inhibitor: fills a gap in the treatment of rare tumors with dual indications.

Luvometinib is an oral small molecule drug that belongs to the MET kinase inhibitor class. It is mainly used to treat patients with tumors carrying specific gene mutations, such as advanced or metastatic cancers in non-small cell lung cancer (NSCLC) driven by MET exon14 skipping mutations.

Me gusta

Comentario

Compartir

Cambio su foto de perfil

2 D

Me gusta

Comentario

Compartir

Cargar más publicaciones

Información

2 Mensajes
Mujer
12/20/03
Viviendo en China

(0)

(0)

(1)

rajesh sharma

(0)

Grupos

(0)